From Tablets to Targeted Therapy: The APHRODITE Era in Male Infertility

Opinion review argues clomiphene and aromatase inhibitors are empirically prescribed without endocrine phenotyping — and proposes gonadotropins instead

Journal: Human Reproduction | Published: 2026-06-01 | Type: Opinion/Review | PMID: 41863283 Authors: Sandro C. Esteves (ANDROFERT private andrology clinic, Brazil), Peter Humaidan (Aarhus University, Denmark) Funding/COI: Not disclosed

Summary

This is an opinion article, not a trial. Esteves and Humaidan argue that idiopathic male infertility has been treated for decades with oral agents — primarily clomiphene citrate and aromatase inhibitors — prescribed empirically, without classifying patients by hormonal phenotype. They introduce the APHRODITE criteria, a proposed stratification framework, and argue it should catalyze a shift toward injectable gonadotropin therapy (FSH and LH/hCG) as earlier-line treatment. The analogy they lean on: ovarian stimulation in IVF evolved from oral agents to gonadotropins and outcomes improved — so male infertility treatment should follow the same arc.

Claims

• Clomiphene citrate and aromatase inhibitors have been prescribed empirically for idiopathic male infertility without rigorous endocrine phenotyping
• The APHRODITE criteria (Addressing male Patients with Hypogonadism and/or infeRtility Owing to altereD, Idiopathic TEsticular function) offer a biologically rational framework for stratifying patients
• Selective estrogen receptor modulators (SERMs) and aromatase inhibitors have "limited efficacy" — characterization is not quantified in the abstract with specific effect sizes
• Exogenous gonadotropins (FSH and LH/hCG) offer "superior physiological control" by analogy with IVF protocols
• FSH and LH/hCG receptor genetic polymorphisms may explain differential treatment responsiveness
• Oral agents "retain a role in specific endocrine profiles" — so the authors are not calling for complete abandonment
• No primary outcome data is reported; the article calls for future prospective RCTs applying APHRODITE criteria

Study Quality

This is an expert opinion piece dressed as a conceptual framework proposal. There is no original data, no cohort, no control group, and no effect size to evaluate. The APHRODITE criteria themselves appear to be newly proposed in this article and have not yet been validated in a prospective trial — the authors explicitly acknowledge this. The analogy to ovarian stimulation in IVF is rhetorical, not mechanistic; male spermatogenesis and female folliculogenesis are not equivalent processes, and parallel evolution of treatment protocols does not constitute evidence.

The framing of gonadotropins as a "paradigm shift" rests on accumulated evidence the authors summarize but do not meta-analyze. Whether that evidence base actually supports upgrading gonadotropins to earlier-line therapy for phenotyped patient subsets is a separate empirical question from whether the APHRODITE framework is conceptually elegant.

Red Flags

• Opinion article with no primary data — highest risk for motivated reasoning
• Lead author runs a private andrology clinic specializing in male infertility; injectable gonadotropin therapy is more expensive and clinic-intensive than oral agents — potential financial conflict of interest not declared
• No COI disclosure despite commercial context
• "Holds promise" and "may catalyze" are aspirational, not evidentiary
• The central analogy (IVF ovarian stimulation → male spermatogenesis) is assumed, not demonstrated
• APHRODITE criteria are self-proposed by the same authors advocating for them — no external validation cited
• Calls for future RCTs as the solution, which implicitly concedes current evidence is insufficient

Strengths

• Correctly identifies a real problem: clomiphene and aromatase inhibitors have been prescribed empirically in idiopathic male infertility for decades with mixed and poorly-evidenced outcomes
• Highlights genetic polymorphisms in FSH and LH/hCG receptors as a plausible mechanistic basis for treatment heterogeneity — a legitimate research direction
• Published in Human Reproduction, a high-impact peer-reviewed journal, suggesting editorial scrutiny
• Authors are senior figures in male reproductive medicine with institutional affiliations

Verdict

This paper is a manifesto, not a trial. Esteves and Humaidan are arguing for a framework they invented, in a journal article they wrote, citing a paradigm shift they are proposing — all without presenting new data. That doesn't make them wrong: the critique of empirical clomiphene prescribing is well-founded, and the call for phenotype-based stratification before hormonal therapy is reasonable. But readers should treat APHRODITE as a hypothesis in need of validation, not a clinical framework in need of adoption. The value here is the argument, not the evidence. Worth reading if you follow male infertility research; worthless as a basis for changing practice until prospective trials test it.